All they're doing is talking, as opposed to 6 months ago when ph 3 trial commencement was 'imminent'. I understand that imminent may have a diiferent meaning in biotech space and hence the delay can be explained. The silence (until now anyway) can't really be explained nor justified.
I'd like to know at what stage discussions are at and whether the goalposts have been changed by Teva. I'd also like to know the other side of the 'early check' on efficacy - could this mean that if things are going well, Teva can pull the plug? I don't think any of this is unreasonable. I put away the rose coloured glasses many years ago.
I'll be cheering as loud as anyone if they come good and I'm still hoing for a 'market cap of CSL' should things go to plan
negative comments., page-6
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2482 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 27045 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |